<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent

I-ELCAP Results Internally Inconsistent, Peter Bach Writes

Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

Telatinib Demonstrates Positive Results in First-Line Treatment

Barret’s Less of a Risk Factor For Cancer of the Esophagus

New Abiraterone Acetate Results Show Greater Benefit Than Before

MGMT Gene Can Determine Disease Aggressiveness

Phase III Study: Lymphoseek Superior to Vital Blue Dye

Intensity Modulated Therapy Safer Than Three-Dimensional Radiation